Survival of tumor cells during treatment would increase the likelihood of recurrence upon treatment withdraw, and may enforce treatment resistance, suggesting that blockade of anti-apoptotic Bcl-2 proteins in combination with anti-estrogens may decrease recurrence and/or resistance in ERα+ breast cancers. This evidence concerns the gene ESR1 and breast cancer.